GENPHARMASEC
LIMITED

Date: 11.08.2026

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 531592

Subject: Outcome of the Meeting of Board of Directors held on Tuesday, 11th August, 2026.

Dear Sir/ Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, i.e. Tuesday, 11th August, 2026, inter alia, considered and approved:

1. The Un-audited Standalone & Consolidated Financial Results of the Company for the quarter ended 30th June, 2026 along with Limited Review Report after these results are reviewed by the Audit Committee.

We further inform you that the Board Meeting commenced at 03:00 p.m. today and concluded at 03:50 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,
Genpharmasec Limited

SOHAN CHATURVEDI
Digitally signed by SOHAN CHATURVEDI
Date: 2026.08.11 15:52:25 +05'30'

GENPHARMASEC LIMITED

Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728

Encl:

1. Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026.
2. Limited Review Reports.

BILIMORIA MEHTA & CO.
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of Genpharmasec Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Genpharmasec Limited ('the Company') for the quarter ended June 30, 2026 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BILIMORIA MEHTA & CO. * FRN: 101490W * CHARTERED ACCOUNTANTS

Mumbai : Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andheri (East), Mumbai - 400 099. Tel : +91 22 6697 2111/12/13, 2837 5522/33
Registered Office : Sethna Buildging, 1st Floor, 216, Shamaldas Gandhi Marg (Princess Street), Mumbai - 400 002. Tel : +91-22-2201 4884/6807
New Delhi : 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi - 110 001. Tel : +91-11-43543750/23736049
Kolkata : Ground Floor, Jyotermoyee Buildging, 27/2, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857
Website : www.bilimoriamehta.in • Email : admin@bilimoriamehta.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The review of standalone unaudited financial results for the period ended June 30, 2025, included in the Statement was carried out and reported by Abhishek S Tiwari & Associates who have expressed unmodified conclusion vide their review report dated August 07, 2025 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

A. mehta

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

Aakash Mehta
Partner
Membership no. 165824
UDIN: 26165824QYEYUH3366
Place of Signature: Mumbai
Date: August 11, 2026

GENPHARMASEC LIMITED
Corporate Identity Number (CIN): L24231MH1992PLC323914
Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026
(All amounts are in INR Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended June 30, 2026 (Unaudited)	Quarter ended March 31, 2026 (Audited)	Quarter ended June 30, 2025 (Unaudited)	For the year ended March 31, 2026 (Audited)
I	Revenue from operations	4,478.44	5,166.42	1,211.32	13,134.94
II	Other Income	97.06	161.79	82.24	486.94
III	**Total Income (I + II)**	**4,575.50**	**5,328.22**	**1,293.55**	**13,621.88**
IV	**Expenses**				
	Purchase of Stock-in-Trade	4,530.97	4,654.89	1,122.56	13,139.94
	Changes in Inventories of Finished goods and Stock-in-Trade	(249.05)	249.20	(69.84)	(533.38)
	Employee benefit expense	24.21	24.62	21.19	97.27
	Finance Costs	12.70	24.75	7.67	59.36
	Depreciation and Amortization Expense	9.77	9.42	4.31	25.60
	Other Expenses	37.19	79.07	37.07	189.39
	Total Expenses (IV)	**4,365.78**	**5,041.94**	**1,122.97**	**12,978.19**
V	**Profit before tax (III - IV)**	**209.72**	**286.27**	**170.58**	**643.69**
VI	**Tax expense:**				
	(1) Current tax	51.66	62.80	16.81	152.32
	(2) Deferred Tax	1.10	(8.34)	(2.15)	(17.73)
	(3) Prior Period Tax	-	-	-	(35.86)
	Total Tax Expense	**52.76**	**54.46**	**14.66**	**98.72**
VII	**Profit for the period (V-VI)**	**156.96**	**231.81**	**155.92**	**544.96**
VIII	**Other Comprehensive Income/(Loss)**				
	(i) Items that will not be reclassified to Profit and Loss				
	(a) Remeasurement of post employment defined benefit plans	-	0.52	-	0.52
	(b) Income tax effect on above	-	(0.13)	-	(0.13)
	(c) Equity instrument through other comprehensive income	16.78	(40.65)	14.26	(50.68)
	(d) Income tax effect on above	-	-	-	-
	Sub-total	**16.78**	**(40.26)**	**14.26**	**(50.29)**
IX	**Total Comprehensive Income/(Loss) for the year (VII + VIII) (Comprising profit and other comprehensive income for the year)**	**173.74**	**191.56**	**170.18**	**494.67**
	Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	**5,537.20**	**5,537.20**	**5,537.20**	**5,537.20**
X	**Earning per equity share**				
	(1) Basic	**0.03**	**0.04**	**0.03**	**0.10**
	(2) Diluted	**0.03**	**0.04**	**0.03**	**0.10**

Notes:

1. The unaudited financial results of the Company for the quarter and year ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards("Indian Accounting Standards("Ind As")As Prescribed under section 133 of the Companies Act, 2013 as amended.

2. The company is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108: Operating Segment. Accordingly, no separate segment information has been provided.

3. The unaudited financial results of the Company for the quarter ended June 30, 2026 have been reviewed by the audit committee on August 11, 2026 and thereafter Board of directors at their meeting held on August 11, 2026.

4. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

For and on behalf of the Board of Directors of
Genpharmasec Limited

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN:09629728

Place: Mumbai
Date : August 11, 2026

Independent Auditor's Review Report on the Quarterly Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of Genpharmasec Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results ('the Statement') of Genpharmasec Limited ('the Holding Company') and its Subsidiaries (the Holding Company and its Subsidiaries together referred to as the "the Group") for the quarter ended June 30, 2026 attached herewith being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the entities mentioned in Annexure I.

BILIMORIA MEHTA & CO.
FRN: 101490W
CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed above as stated in paragraph 3 and based on the consideration of the review reports of the other auditors and unaudited financial results referred to in paragraph 6 & 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of one subsidiary, whose unaudited interim financial results include total revenue from operations of Rs. 271,92 lakhs, total net loss after tax of Rs. 140.24 lakhs total comprehensive loss of Rs. 140.24 lakhs for the quarter ended June 30, 2026, as considered in the Statement, which has been reviewed by their independent auditor.

   The independent auditor's reports on interim financial results of this entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditor and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of one of the subsidiaries which is located outside India have been prepared in accordance with accounting principles generally accepted in their respective countries. The Holding Company's management has converted the financial results of such subsidiary located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. The financial results and other financial information reflect total revenue of Rs. 220.67, total Net loss after tax of Rs. 2.64 lakhs, total comprehensive loss of Rs. 2.64 lakhs for the quarter ended June 30, 2026 and We have reviewed these conversion adjustments made by the Holding Company's management.

   The unaudited interim financial results and other unaudited financial information of the subsidiary have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

8. The review of consolidated unaudited financial results for the period ended June 30, 2025, included in the Statement was carried out and reported by Abhishek S Tiwari & Associates who have expressed unmodified conclusion vide their review report dated August 7, 2025 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

AMehta

Aakash Mehta
Partner
Membership no. 165824
UDIN: 26165824UOTAXO7625
Place of Signature: Mumbai
Date: August 11, 2026

Annexure -1

Sr. No	Particulars	Status
1	Clinigenome India Private Limited	Subsidiary
2	Genpharmasec Middle East DMCC	Subsidiary
3	Derren Healthcare Private Limited	Subsidiary

BILIMORIA MEHTA & CO.
FRN:
101490W
CHARTERED ACCOUNTANTS

GENPHARMASEC LIMITED
Corporate Identity Number (CIN): L24231MH1992PLC323914
Statement of Consolidated Unaudited Financial results for the Quarter ended 30th June, 2026
(All amounts are in INR Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended June 30, 2026 (Unaudited)	Quarter ended March 31, 2026 (Audited)	Quarter ended June 30, 2025 (Unaudited)	For the year ended March 31, 2026 (Audited)
I	Revenue from operations	4,971.03	5,542.92	1,204.32	13,993.77
II	Other Income	37.30	101.57	69.48	315.70
III	**Total Income (I + II)**	**5,008.34**	**5,644.49**	**1,273.80**	**14,309.47**
IV	**Expenses:**				
	Cost of materials consumed	105.90	12.32	12.86	284.02
	Purchase of Stock-in-Trade	4,748.43	4,654.89	1,122.56	13,139.94
	Changes in Inventories of Finished goods, Stock-in-Trade and Work-in-progress	(259.90)	347.02	(104.59)	(565.96)
	Employee benefit expense	110.79	106.87	34.96	387.00
	Financial costs	39.92	48.11	12.26	124.03
	Depreciation and amortization expense	67.43	67.53	26.59	216.84
	Other expenses	170.01	222.47	44.55	626.54
	Total Expenses (IV)	**4,982.57**	**5,459.21**	**1,149.19**	**14,212.40**
V	**Profit before tax (III - IV)**	**25.77**	**185.28**	**124.61**	**97.07**
VI	**Tax expense:**				
	(1) Current tax	51.66	62.80	16.81	152.32
	(2) Deferred Tax	(8.53)	(12.82)	(13.72)	(75.40)
	(3) Prior Period Tax	-	-	-	(35.86)
	Total Tax Expense	**43.13**	**49.98**	**3.09**	**41.06**
VII	**Profit/(Loss) for the period (V-VI)**	**(17.37)**	**135.30**	**121.52**	**56.01**
	Profit/(loss) Attributable to				
	i. Equity Holder of Parent	**25.98**	**148.53**	**121.52**	**160.33**
	ii. Non Controlling Interest	**(43.34)**	**(13.23)**	**(0.00)**	**(104.32)**
VIII	**Other Comprehensive Income/(Loss)**				
	(i) Items that will not be reclassified to Profit and Loss	-	-	-	-
	(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	0.68
	(b) Income tax effect on above	-	-	-	(0.17)
	(c) Equity instrument through other comprehensive income	16.78	(40.65)	14.26	(50.68)
	(d) Income tax effect on above	-	-	-	-
	Sub-total	**16.78**	**(40.65)**	**14.26**	**(50.17)**
IX	**Total Comprehensive Income/(Loss) for the year (VII + VIII)** **(Comprising profit and other comprehensive income for the year)**	**(0.58)**	**94.65**	**135.78**	**5.84**
	Total Comprehensive Income/(Loss) Attributable to				
	i. Equity Holder of Parent	**42.76**	**107.88**	**135.79**	**110.16**
	ii. Non Controlling Interest	**(43.34)**	**(13.23)**	**(0.00)**	**(104.32)**
	Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	**5,537.20**	**5,537.20**	**5,537.20**	**5,537.20**
X	**Earning per equity share**				
	(a) Basic	**(0.00)**	**0.02**	**0.02**	**0.01**
	(b) Diluted	**(0.00)**	**0.02**	**0.02**	**0.01**

1.The unaudited financial results of the Group for the quarter and year ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards("Indian Accounting Standards("Ind As")As Prescribed under section 133 of the Companies Act, 2013 as amended.

2.Segment Reporting has been annexed in Annexure 1.

3.The unaudited financial results of the Group for the quarter ended June 30, 2026 have been reviewed by the audit committee on August 11, 2026 and thereafter Board of directors at their meeting held on August 11, 2026.

4.The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

For and on behalf of the Board of Directors of Genpharmasec Limited

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN:09629728

Place: Mumbai
Date: August 11, 2026

GENPHARMASEC LIMITED
Corporate Identity Number (CIN): L24231MH1992PLC323914
"ANNEXURE - I"
Consolidated Statement of unaudited Segment-wise Revenue, Results, Assets and Liabilities
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter ended June 30, 2026 (Unaudited)	Quarter ended March 31, 2026 (Audited)	Quarter ended June 30, 2025 (Unaudited)	For the year ended March 31, 2026 (Audited)
Segment Revenue				
Pharmaceuticals	4,478.44	5,166.43	1,167.09	13,087.05
Laboratory Testing	-	-	-	100.47
Manufacturing & Processing	271.92	376.49	37.24	806.24
Unallocable	220.67	-	-	-
Total Revenue	4,971.03	5,542.92	1,204.32	13,993.77
Segment Results (Profit before tax and interest)				
Pharmaceuticals	222.41	311.02	178.25	703.05
Laboratory Testing	(29.20)	(43.94)	-	(158.87)
Manufacturing & Processing	(125.07)	(33.14)	(41.38)	(322.44)
Unallocable	(2.45)	(0.56)	-	(0.65)
Total	65.68	233.39	136.87	221.09
Less				
(i) Unallocated Finance Cost	(39.92)	(48.11)	(12.26)	(124.03)
(ii) Other unallocable expenditure net of unallocable income	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-
Profit Before Tax	25.77	185.28	124.61	97.07
Segment Assets				
Pharmaceuticals	6,918.07	6,189.42	2,023.11	6,189.42
Laboratory Testing	734.65	753.26	884.47	753.26
Manufacturing & Processing	3,166.38	2,992.08	-	2,992.08
Unallocable	4,809.25	3,880.58	5,368.74	3,880.58
Total	15,628.35	13,815.34	8,276.32	13,815.34
Segment Liabilities				
Pharmaceuticals	3,936.34	3,856.43	968.78	3,856.43
Laboratory Testing	791.60	136.85	211.08	136.85
Manufacturing & Processing	1,355.59	1,194.37	-	1,194.37
Unallocable	2,980.91	2,063.22	432.71	2,063.22
Total	9,064.44	7,250.86	1,612.57	7,250.86

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board of Directors of
Genpharmasec Limited

Soham

Sohan Chaturvedi
(Whole Time Director & CFO)
DIN : 09629728

GENPHARMASEC LIMITED
KANDIVALI (E) MUMBAI 400 101.

Place: Mumbai
Date : August 11, 2026